Results 41 to 50 of about 2,936,436 (245)

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

Molecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault, Capucine Heraud, Mélissa Correia de Oliveira, Véronique Neaud, Valérie Valesco, Valérie Prouzet‐Mauleon, Béatrice Turcq, Jean‐William Dupuy, Anne‐Aurélie Raymond, Sabrina Croce, Frédéric Saltel, Valérie Lagrée, Violaine Moreau   +12 more
wiley   +1 more source

Three‐year follow‐up of the use of a levonorgestrel‐releasing intrauterine system in hormone replacement therapy

Acta Obstetricia et Gynecologica Scandinavica, 1997
Background. The efficacy of a levonorgestrel‐releasing intrauterine system in opposing endometrial proliferation and in preventing bleeding was studied in peri‐ and postmenopausal women receiving estrogen replacement therapy. Methods.
Satu Suhonen, Teddy Holmström, Pekka Lähteenmäki   +2 more
doaj   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Changes in Hemostasis and Lipid Metabolism in Postmenopausal Women Receiving Hormone Replacement Therapy: Effects of Natural and Synthetic Progestogens

Taiwanese Journal of Obstetrics & Gynecology, 2004
Objective: In this study, we evaluated hemostatic factors related to cardiovascular disease in postmenopausal women receiving estrogen or combined progestogen replacement therapy.
Li-Fen Teng, Fang-Ping Chen
doaj   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

Advanced Healthcare Materials, EarlyView.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin B. Waghamode, Shubham Khot, Rajiya Khan, Ravi Hole, Shankar M. Dhobale, Manoj Aswar, Keshav Raj Paudel   +8 more
wiley   +1 more source

Effects of estrogen replacement therapy on symptoms and clinical parameters in post menopausal women [PDF]

المجلة العراقية للصيدلة, 2011
Objective: To evaluate the effect of oral estrogen replacement therapy (ERT) in healthy postmenopausal women on lipid profile, body mass index (BMI), blood pressure, and blood glucose; and on postmenopausal symptoms.
Norjihan Ali Shaban, Kawa Dizaye
doaj   +1 more source

Hormone Replacement Therapy Does Not Eliminate Risk Factors for Joint Complications following Total Joint Arthroplasty: A Matched Cohort Study

Pathophysiology, 2023
Aging causes a reduction in testosterone and estrogen, which is linked to diminished bone mineral density. Hormone replacement therapy and its effect on the outcome of joint arthroplasties is unclear.
Lacee K. Collins, Matthew W. Cole, Timothy L. Waters, Michael Iloanya, Patrick A. Massey, William F. Sherman   +5 more
doaj   +1 more source

Oestrogen replacement therapy may improve memory functioning in the absence of APOE e4 [PDF]

, 2004
There is currently intense controversy regarding the use of hormone replacement therapy (HRT) in postmenopausal women, in relation to its therapeutic efficacy in Alzheimer's disease (AD).
Stuckey, B.G.A., Laws, S.M., Nolan, D., Hewson-Bower, B., Baker, L.D., Foster, J.K., Clarnette, R., Burkhardt, M.S., Martins, R.N., Gandy, S.E., Craft, S.   +10 more
core  

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Congenital aromatase deficiency in an adult male: A case report of clinical course and symptom reversal with estrogen supplementation

Urology Case Reports
Congenital aromatase deficiency is an autosomal recessive CYP19A1 loss-of-function disorder that blocks conversion of androgens to estrogens. A man with homozygous CYP19A1 c.628G > A (exon 5) presented with longstanding fatigue, low libido, and desire to
Peyton Coady, Arnaav Walia, Beatriz Hernandez, David E. Hinojosa-Gonzalez, Adnan El-Achkar, Mohit Khera   +5 more
doaj   +1 more source